| Name | Title | Contact Details |
|---|
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our strength lies in our exclusive focus and singular influence on the worldwide effort to end T1D.
CRC Health Corporation (CRC) is a provider of substance abuse treatment services and youth treatment services in the United States.
The b.well connected health platform provides an all-in-one integrated solution for consumer engagement, holistic health management, and cost containment. Our use of longitudinal aggregated data creates a complete picture of health for each consumer and is aggregated to allow for true population health management. Our unique approach to partner integration allows our customers to change their programs in real time as the health needs of their population change, not on an annual sales cycle. With the b.well platform there is one contract, one implementation and the elimination of point-solution fatigue. We provide real-time transparent dashboards to all customers highlighting return on investment, cost containment opportunities, engagement metrics and outreach campaign outcomes, clinical risk factors and disease states. b.well supports health plans, health systems, employers and pharmaceutical companies to bring their digital strategy to life and enables them to provide their employees, members and patients with the one thing they do not have today; one place to manage all aspects of their health.
Kelley X-Ray Co is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.